Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 10Active not recruiting 3Terminated 1Suspended 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 234Neoplasms 206Carcinoma, Non-Small-Cell Lung 100Colorectal Neoplasms 98Prostatic Neoplasms 93Lung Neoplasms 78Multiple Myeloma 53Melanoma 51Pancreatic Neoplasms 50Head and Neck Neoplasms 49Neoplasm Metastasis 47Leukemia, Myeloid, Acute 43Carcinoma, Hepatocellular 43Ovarian Neoplasms 39Brain Neoplasms 39Squamous Cell Carcinoma of Head and Neck 36Recurrence 35Glioblastoma 33Uterine Cervical Neoplasms 32Sarcoma 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Glioma 29Lymphoma, Non-Hodgkin 28Lymphoma 27Colonic Neoplasms 27Stomach Neoplasms 26Carcinoma, Renal Cell 26Lymphoma, Follicular 25Esophageal Neoplasms 24Rectal Neoplasms 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hereditary Sensory and Autonomic Neuropathies × 90 days × Clear all
NCT06308263 2026-04-23

Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 1 Completed
12 enrolled

Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡